Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 1Lymphoid 1

Conditions

Solid Tumor Cancer 1Lymphoma, Non-Hodgkin 1Hodgkin Disease 1

Interventions

Cyclophosphamide 1499Cisplatin 1435Paclitaxel 1340Radiotherapy 1310Carboplatin 1267Gemcitabine 1226Docetaxel 1133Bevacizumab 1070Fluorouracil 906Doxorubicin 805Dexamethasone 755Rituximab 744Capecitabine 735Oxaliplatin 709pembrolizumab 700Etoposide 679Irinotecan 639Filgrastim 624Cytarabine 587Nivolumab 586Leucovorin 583Vincristine 517Cetuximab 479Prednisone 478Bortezomib 474Trastuzumab 468Erlotinib Hydrochloride 467Surveys and Questionnaires 460Methotrexate 444Lenalidomide 436

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × SB 743921 × Clear all
NCT00343564 2020-01-13

A Study of SB-743921 in Non-Hodgkin Lymphoma and Hodgkin Lymphoma

Cytokinetics

Phase 1/2 Completed
68 enrolled 26 charts
Lymphoid

Hodgkin Disease, Lymphoma, Non-Hodgkin

NCT00136513 2008-10-16

SB-743921 In Patients With Solid Tumors

GlaxoSmithKline

Phase 1 Completed
30 enrolled
Other solid neoplasm

Solid Tumor Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡